To confirm the relevance of potential targets emerging from kinase inhibitor screening, we tested the efficacy of drug analogues on HCT116 and two representative CRC-SC lines, i.e. #1.1 and #18, chosen based on their different KRAS and TP53 status. This evidence concerns the gene KRAS and colorectal carcinoma.